Macrophage Migration Inhibitory Factor: New Insights into the Pathogenesis of Alcoholic Liver Disease

2019 ◽  
Vol 44 (1) ◽  
pp. 19-22
Author(s):  
Hua Wang ◽  
Rui Liu
Keyword(s):  
Liver Disease ◽  
Alcoholic Liver Disease ◽  
Migration Inhibitory Factor ◽  
Macrophage Migration Inhibitory Factor ◽  
Inhibitory Factor ◽  
Macrophage Migration

scholarly journals Macrophage Migration Inhibitory Factor as a Novel Biomarker of Portopulmonary Hypertension

2016 ◽  
Vol 6 (4) ◽  
pp. 498-507 ◽  
Author(s):  
Hilary M. DuBrock ◽  
Josanna M. Rodriguez-Lopez ◽  
Barbara L. LeVarge ◽  
Michael P. Curry ◽  
Paul A. VanderLaan ◽  
...  
Keyword(s):  
Liver Disease ◽  
Migration Inhibitory Factor ◽  
Predictive Value ◽  
Pulmonary Circulation ◽  
Macrophage Migration Inhibitory Factor ◽  
Inhibitory Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Heart Catheterization ◽  
Macrophage Migration ◽  
Portopulmonary Hypertension

Portopulmonary hypertension (POPH) is a poorly understood complication of liver disease associated with significant morbidity and mortality. We sought to identify novel biomarkers of POPH disease presence and severity. We performed a prospective, multicenter, case-control study involving patients with liver disease undergoing right heart catheterization. POPH cases were defined as a mean pulmonary arterial pressure (mPAP) ≥25 mmHg and pulmonary vascular resistance (PVR) >240 dynes·s·cm−5. Plasma samples were collected from the systemic and pulmonary circulation, and antibody microarray was used to identify biomarkers. Characterization and validation of a candidate cytokine, macrophage migration inhibitory factor (MIF), was performed using enzyme-linked immunosorbent assay. Continuous variables were compared using a Mann-Whitney U test and correlated with disease severity using Spearman correlation. MIF levels were elevated in both the systemic and pulmonary circulation in patients with POPH compared with controls (median MIF level [interquartile range] in systemic circulation: 46.68 ng/mL [32.31–76.04] vs. 31.19 ng/mL [26.92–42.17], P = 0.009; in pulmonary circulation: 49.59 ng/mL [35.90–108.80] vs. 37.78 [21.78–45.53], P = 0.002). In patients with POPH, MIF levels were positively correlated with PVR ( r = 0.58, P = 0.006) and inversely correlated with cardiac output ( r = −0.57, P = 0.007). MIF >60 ng/mL or tricuspid regurgitation gradient >50 mmHg had a 92% sensitivity and specificity for the diagnosis of POPH, with a positive predictive value of 86% and a negative predictive value of 96%. MIF is a promising novel biomarker of POPH disease presence and severity in patients with liver disease and portal hypertension.

scholarly journals Involvement of exercise-induced macrophage migration inhibitory factor in the prevention of fatty liver disease

2013 ◽  
Vol 218 (3) ◽  
pp. 339-348 ◽  
Author(s):  
Hyo Youl Moon ◽  
Parkyong Song ◽  
Cheol Soo Choi ◽  
Sung Ho Ryu ◽  
Pann-Ghill Suh
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Lipid Oxidation ◽  
Migration Inhibitory Factor ◽  
Fatty Liver Disease ◽  
Macrophage Migration Inhibitory Factor ◽  
Human Hepatocyte ◽  
Inhibitory Factor ◽  
Macrophage Migration ◽  
Nonalcoholic Fatty Liver

Physical inactivity can lead to obesity and fat accumulation in various tissues. Critical complications of obesity include type II diabetes and nonalcoholic fatty liver disease (NAFLD). Exercise has been reported to have ameliorating effects on obesity and NAFLD. However, the underlying mechanism is not fully understood. We showed that liver expression of macrophage migration inhibitory factor (MIF) was increased after 4 weeks of treadmill exercise. Phosphorylation of AMP-activated protein kinase and acetyl-CoA carboxylase in human hepatocyte cell lines was enhanced after MIF treatment. These responses were accompanied by increases in lipid oxidation. Moreover, inhibition of either AMPK or cluster of differentiation 74 resulted in inhibition of MIF-induced lipid oxidation. Furthermore, the administration of MIF to a human hepatocyte cell line and mice liver reduced liver X receptor agonist-induced lipid accumulation. Taken together, these results indicate that MIF is highly expressed in the liver during physical exercise and may prevent hepatic steatosis by activating the AMPK pathway.

scholarly journals The role of macrophage migration inhibitory factor in autoimmune liver disease

Hepatology ◽  
2013 ◽  
Vol 59 (2) ◽  
pp. 580-591 ◽  
Author(s):  
David N. Assis ◽  
Lin Leng ◽  
Xin Du ◽  
Clarence K. Zhang ◽  
Gerrit Grieb ◽  
...  
Keyword(s):  
Liver Disease ◽  
Migration Inhibitory Factor ◽  
Macrophage Migration Inhibitory Factor ◽  
Autoimmune Liver Disease ◽  
Inhibitory Factor ◽  
Macrophage Migration

287: Macrophage Migration Inhibitory Factor and its Receptor CD74 are Upregulated in the Urothelium of Interstitial Cystitis Patients

2006 ◽  
Vol 175 (4S) ◽  
pp. 95-96 ◽  
Author(s):  
Pedro L. Vera ◽  
Kenneth A. lczkowski ◽  
Robert M. Moldwin ◽  
Leslie Kushner ◽  
Katherine L. Meyer-Siegler
Keyword(s):  
Interstitial Cystitis ◽  
Migration Inhibitory Factor ◽  
Macrophage Migration Inhibitory Factor ◽  
Inhibitory Factor ◽  
Macrophage Migration
Sign in / Sign up

Export Citation Format

Share Document